Clinical Trials
17
Active:7
Completed:9
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:4
Phase 2:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)β’ Click on a phase to view related trials
Phase 3
6 (46.2%)Phase 1
4 (30.8%)Phase 2
2 (15.4%)Early Phase 1
1 (7.7%)The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast
Early Phase 1
- Conditions
- Healthy
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 15
- Registration Number
- NCT02335515
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 64
- Registration Number
- NCT00830102
- Locations
- π¬π§
Investigational site, Slough, United Kingdom
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: SKP FlutiForm HFA pMDI
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 280
- Registration Number
- NCT00747318
- Locations
- π²π½
Investigational Site, Zapopan, Zapopan Jalisco, Mexico
πΊπ¦Investigational site, Zaporizhzhya, Ukraine
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
Phase 2
Completed
- Conditions
- Mild to Moderate Asthma
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 39
- Registration Number
- NCT00734292
- Locations
- πΊπΈ
Investigational Site, West Allis, Wisconsin, United States
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiFormβ’ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 160
- Registration Number
- NCT00657774
- Locations
- πΊπΈ
Investigational site, San Antonio, Texas, United States
πΊπΈInvestigational Site, Lake Oswego, Oregon, United States
- Prev
- 1
- 2
- Next
News
No news found